IPOX® Research Analyst Lukas Muehlbauer was featured in Reuters discussing Wealthfront’s $2.63 billion Nasdaq debut. While the fintech raised $484.6 million, its flat opening highlighted ongoing market caution. Muehlbauer noted that "investors are still selective," distinguishing between high-profile wins and mixed broader performance. His commentary underscores the critical nuance required when analyzing shifting sentiment within the recovering fintech IPO landscape.

In a recent Reuters article, IPOX® CEO Josef Schuster analyzes the successful $462.5 million IPO of Lumexa Imaging amidst the year-end market rush. Schuster highlights that while investor appetite exists for the "right deal," there is notable caution regarding sectors with poor post-IPO returns, such as Silicon Valley-backed crypto and AI ventures. Read more about his insights on the current selective IPO landscape.

Construction tech firm EquipmentShare revealed significant revenue growth in its recent US IPO paperwork. IPOX® Research Analyst Lukas Muehlbauer provided key insights on the filing, noting the company’s sensitivity to interest rates due to capital deployment for its rental fleet. Muehlbauer also discussed the broader market trend, suggesting companies are rushing filings to avoid potential volatility and uncertainty surrounding Federal Reserve leadership changes in 2026.

In a recent Reuters article, IPOX® CEO Josef Schuster analyzes Medline’s targeted $55 billion listing, poised to be 2025’s largest IPO. Dr. Schuster highlights the deal as a critical test for market breadth beyond tech, describing the company as an "amazing American growth story." His commentary underscores the vital role of public markets in funding expansion as Medline seeks to raise over $5 billion in this blockbuster offering.

IPOX® Analyst Lukas Muehlbauer comments on Andersen Group's $1.75 billion IPO in a recent Reuters article. Muehlbauer describes the listing as a "resurrection story" for the brand formerly linked to Arthur Andersen. He notes that the decision to list now suggests management is prioritizing immediate capital access over 2026 volatility, while strategically aligning the deal with strong financial results from tax-extension seasonality.

A recent Bloomberg article examines the contraction of Canada’s public markets, where delistings are outpacing IPOs. IPOX® CEO Josef Schuster weighs in on the lack of domestic momentum, noting that Canadian firms are growing but often listing elsewhere. He emphasizes the need for a "strong first deal" to act as a catalyst and reignite the Canadian IPO market for the coming year.

In Kiplinger, David Milstead examines the surging U.S. IPO market, cautioning against risks from heavy AI and cryptocurrency concentration. He suggests navigating this volatility through diversified ETFs rather than individual stocks. Milstead highlights the First Trust US Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index. Up 39.3% in 2025, FPX captures major recent listings, offering investors broad exposure with reduced volatility compared to potentially riskier alternatives in this heated market.

Wealthfront targets a $2.05 billion valuation in its upcoming U.S. IPO. In recent Reuters coverage, IPOX® Associate Lukas Muehlbauer discusses the firm's strategic positioning at the "intersection of artificial intelligence and fintech." Muehlbauer highlights that while investor demand for new listings remains high, market sentiment is still susceptible to volatility. Read the full post for insights on Wealthfront’s plans and the current IPO market landscape.

Sports technology firm Enhanced plans to go public via a $1.2 billion merger with A Paradise Acquisition Corp, highlighting a resurgence in the blank-check market. IPOX CEO Josef Schuster noted that "SPACs are here to stay," driven by the success of innovative companies from the previous cycle. Co-founded by Christian Angermayer, the company plans to host sporting events where performance-enhancing drugs are allowed. The company expects to list on the Nasdaq under the ticker "ENHA" in the first half of 2026.

In a new Bloomberg feature, IPOX® Schuster Founder Josef Schuster discusses the impact of the recent crypto crash on the US IPO market. With returns from new listings waning, Schuster notes that crypto is currently the "least favored sector" due to sustained investor losses. He suggests that while upcoming issuers may not need to postpone their debuts, they will likely face pressure to adjust pricing expectations downward. Read more about the challenging landscape for digital asset public offerings.

On November 20, Central Bancompany shares climbed in their Nasdaq debut, securing a $5.26 billion valuation after raising $373 million. The listing continues a strong year for financial IPOs. IPOX® CEO Josef Schuster commented on investor confidence, stating, “The bank's successful trajectory fits well with investors looking for exposure to banks operating in markets with strong economic growth.” The Missouri-based lender manages $19.2 billion in assets.

Reuters highlighted Klook’s strong 2024 performance, revealing a 24% rise in revenue in its U.S. IPO filing. The SoftBank-backed platform seeks to list on the New York Stock Exchange as global travel rebounds. IPOX® Vice President Kat Liu noted Klook’s advantage in the underpenetrated travel experiences market while cautioning about thinner margins and fragmented supply. Goldman Sachs leads the offering’s underwriting team.

Dubai-based AIR, owner of the popular hookah brand Al Fakher, announced a $1.75 billion SPAC merger with Cantor Equity Partners III to list on Nasdaq as AIIR in 2026. The deal signals SPAC resurgence amid recovering markets, with the IPOX® SPAC Index outperforming equities on strong aftermarket performance. IPOX® Research Associate Lukas Muehlbauer highlighted lower interest rates easing capital access and diminishing risk perceptions for SPACs.

IPOX® Research Analyst Lukas Muehlbauer commented on Grupo Aeromexico's NYSE debut, where shares opened at $19.16, valuing the airline at $2.8 billion post-bankruptcy. The IPO raised $222.8 million amid regulatory scrutiny over Mexican routes and Delta joint venture. Muehlbauer noted investors are overlooking immediate concerns, buoyed by Aeromexico's recovery and efficient restructuring, though disputes may pressure stock performance until resolved.

In this First Trust Webinar, IPOX® Senior Investment Manager Kat Liu, CFA, delivers essential insights into the US IPO market and why IPO investment is important. She details the First Trust U.S. Equity Opportunities ETF (FPX), which employs systematic screening and a patented "1000 trading days" framework. FPX achieved 12.27% annualized returns since 2006 (as of 9/30/25), outperforming the S&P 500 with nearly 40% year-to-date gains.

Smaller Saudi firms like Cherry Trading Co. ($67M IPO) and Almasar Alshamil Education Co. ($160M) are testing the subdued equity market, where valuation discipline is key amid investor caution. MENA IPOs raised $5.1B this year, but many trade below offer prices, contrasting global gains. IPOX® Research Associate Lukas Muehlbauer notes: "Newly listed stocks across the Middle East and North Africa have declined this year... global asset managers expect more disciplined pricing." This signals a fundamentals-driven shift.

In a Reuters feature on Xanadu Quantum Technologies’ $3.6 billion SPAC merger with Crane Harbor Acquisition Corp., IPOX® Vice President Kat Liu highlighted the strategic advantages of the SPAC route. Liu noted that such deals provide “a large, single-tranche capital infusion, extending the company’s R&D runway and ensuring survival in a market where venture appetite for capital-intensive quantum projects has cooled.”

In Bloomberg’s ECM Watch, IPOX® Founder Josef Schuster commented on the surge in U.S. industrial spinoffs following Honeywell’s and DuPont’s high-profile separations. Schuster noted that “the dynamics these companies are creating are pretty solid,” emphasizing that many recent spin-offs are backed by strong fundamentals. While early trading can see selling pressure, he highlighted that size and index inclusion often support long-term performance.

In a recent Reuters article, IPOX® VP Kat Liu commented on travel tech firm Navan’s $923 million Nasdaq debut, highlighting the growing investor interest in AI-driven IPOs. Liu noted that, “For Navan to be a true credible AI story, it needs to demonstrate some unique and hard-to-replicate value.” Her remarks underscore IPOX’s continued insight into how innovation and authenticity shape success in today’s evolving IPO market.

Reuters highlights Medline’s blockbuster U.S. IPO filing, which could value the healthcare giant at up to $50 billion. Commenting on the deal, IPOX® Research Associate Lukas Muehlbauer said the offering “signals that the IPO market remains wide open despite the shutdown” and will serve as a key test of investor confidence heading into 2026. Medline’s listing, expected to be one of the year’s largest, underscores renewed strength in the U.S. IPO market after several years of subdued activity.